Who Paid My Doc
Kymriah
Biological Oncology
NDC 0078-0846-19
General payments
$912,591
Research payments
$23,481,002
Through program year 2024, $912,591 in general payments and $23,481,002 in research payments were reported against Kymriah (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $16,654 | 12 |
| 2024 | Research | $45,100 | 10 |
| 2023 | General | $10,357 | 18 |
| 2023 | Research | $10,150 | 2 |
| 2022 | General | $75,894 | 210 |
| 2022 | Research | $4,311,405 | 225 |
| 2021 | General | $214,076 | 279 |
| 2021 | Research | $6,057,904 | 194 |
| 2020 | General | $79,861 | 101 |
| 2020 | Research | $8,199,333 | 201 |
| 2019 | General | $515,749 | 856 |
| 2019 | Research | $4,857,109 | 213 |
Breakdown
The top 5 of 10 recipients; each share is of general payments naming this product in 2024.
Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
1,476 general · 845 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.